Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

[Novel morphological and molecular aspects of lung cancer].

Warth A, Stenzinger A, Weichert W.

Pathologe. 2013 Sep;34(5):419-28. doi: 10.1007/s00292-013-1787-9. Review. German.

PMID:
23900599
2.

[Morphological and molecular pathology of lung cancer].

Petersen I.

Pathologe. 2010 Oct;31 Suppl 2:204-10. doi: 10.1007/s00292-010-1371-5. Review. German.

PMID:
20852864
3.

Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.

Schildhaus HU, Deml KF, Schmitz K, Meiboom M, Binot E, Hauke S, Merkelbach-Bruse S, Büttner R.

Mod Pathol. 2013 Nov;26(11):1468-77. doi: 10.1038/modpathol.2013.95. Epub 2013 Jun 7.

4.

[Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].

Warth A.

Pathologe. 2015 Nov;36 Suppl 2:194-200. doi: 10.1007/s00292-015-0085-0. Review. German.

PMID:
26391251
5.
6.

Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.

Shaozhang Z, Xiaomei L, Aiping Z, Jianbo H, Xiangqun S, Qitao Y.

Genes Chromosomes Cancer. 2012 Oct;51(10):925-32. doi: 10.1002/gcc.21976. Epub 2012 Jun 27.

PMID:
22736493
7.

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y.

J Thorac Oncol. 2008 Jan;3(1):13-7. doi: 10.1097/JTO.0b013e31815e8b60.

8.

[Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology].

Savic S, Bihl MP, Bubendorf L.

Pathologe. 2012 Jul;33(4):301-7. doi: 10.1007/s00292-012-1577-9. Review. German.

PMID:
22711372
9.

There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.

Clery E, Pisapia P, Feliciano S, Vigliar E, Marano A, De Luca C, Malapelle U, Troncone G, Bellevicine C.

J Clin Pathol. 2017 Sep;70(9):798-802. doi: 10.1136/jclinpath-2017-204370. Epub 2017 Mar 31.

PMID:
28363898
10.
11.
12.

Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.

Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi K, Seto T, Takenoyama M, Ichinose Y, Sugio K.

Surg Today. 2016 Sep;46(9):1091-8. doi: 10.1007/s00595-015-1295-z. Epub 2015 Dec 28.

PMID:
26711128
13.

[Translational research and diagnostics in lung cancer].

Göke F, Perner S.

Pathologe. 2012 Nov;33 Suppl 2:269-72. doi: 10.1007/s00292-012-1664-y. Review. German.

PMID:
22968733
14.

Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.

Driver BR, Portier BP, Mody DR, Deavers M, Bernicker EH, Kim MP, Teh BS, Santacruz JF, Kopas L, Munden RF, Cagle PT.

Arch Pathol Lab Med. 2016 Apr;140(4):312-7. doi: 10.5858/arpa.2015-0361-OA. Epub 2015 Oct 2.

PMID:
26430808
15.

Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.

Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S.

J Thorac Oncol. 2012 Jan;7(1):105-14. doi: 10.1097/JTO.0b013e3182352a45.

16.

[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].

Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Chinese.

PMID:
23157740
17.

EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.

J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.

18.

Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, Popat S.

J Thorac Oncol. 2010 Apr;5(4):436-41. doi: 10.1097/JTO.0b013e3181c6ed9b.

19.

The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.

Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, Plaza C, Dominguez N, Torres M, Madrigal L, Rubio-Viqueira B, Belda-Iniesta C, Hidalgo M, López-Ríos F.

Histopathology. 2013 Mar;62(4):609-16. doi: 10.1111/his.12037. Epub 2013 Feb 5.

20.

Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.

Oshita F, Kasajima R, Miyagi Y.

J Exp Ther Oncol. 2016 Jul;11(3):189-194.

PMID:
28471124

Supplemental Content

Support Center